SMShaji Kumar

Shaji Kumar, MD, of Mayo Clinic Rochester, discussed findings from a substudy of the RedirecTT-1 trial examining talquetamab plus teclistamab as a dual targeting approach to extramedullary myeloma. Dr. Kumar explored the safety and efficacy of this combination across subgroups, including patients who received prior bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapy. This transcript has been edited for clarity.